Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Palisade Bio (Nasdaq: PALI) will present virtually at the Needham & Co. 25th Annual Healthcare Conference April 14–17, 2026.

Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) will present virtually at the Needham & Co. 25th Annual Healthcare Conference April 14–17, 2026. The company presentation by CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones is scheduled for April 16, 2026, 2:15–2:55 PM ET in Track 3.

A live webcast will be available on the Events page of the Investors section at palisadebio.com, with a replay archived for a limited time. Management will be available for one-on-one meetings with qualified, registered investors.

Argus Apr 8 session

-2.09% close to close Open Argus

Details

News Market Reaction – PALI

On Apr 8, the day this news came out, PALI closed 2.09% below the previous close.

Data tracked by StockTitan Argus for the Apr 8 session.

Market Context

This announcement centers on Palisade Bio’s participation in the Needham healthcare conference, cont...

Analysis

This announcement centers on Palisade Bio’s participation in the Needham healthcare conference, continuing a pattern of active investor outreach alongside clinical progress for PALI-2108. Recent history includes positive Phase 1b data, multiple scientific presentations, and an 8-K documenting a $3.0 million share sale to support a planned Phase 2 study. Investors may focus on upcoming trial milestones, financing disclosures, and any new details shared during the April 16 presentation.

Key Figures

Market cap: $323,509,885 Private placement proceeds: $3.0 million Shares issued: 1,536,885 shares +5 more

Market cap

$323,509,885

Pre-news market value for PALI

Private placement proceeds

$3.0 million

8-K: shares sold to Iterative Health affiliate

Shares issued

1,536,885 shares

8-K: common stock sold in private transaction

Issue price

$1.952 per share

8-K: matches 5-day average closing price

RA Capital ownership

15,746,829 shares (9.99%)

Schedule 13G/A as of Dec 31, 2025

Point72 ownership

10,495,252 shares (7.0%)

Schedule 13G/A as of Dec 31, 2025

Perceptive ownership

15,200,117 shares (9.99%)

Schedule 13G/A with pre-funded warrants

CMO RSU grant

787,000 RSUs

Form 4 grant on Feb 9, 2026

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Clinical trial data

   24h Move

   -1.7%

   Reported positive Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease.

2. Mar 02

   Investor conferences

   24h Move

   +2.3%

   Announced participation in TD Cowen and Leerink investor conferences in March 2026.

3. Feb 23

   Clinical data update

   24h Move

   +0.6%

   Presented ECCO 2026 data showing colon‑targeted activity and encouraging safety for PALI-2108.

4. Feb 17

   Advisory appointment

   24h Move

   -1.7%

   Appointed IBD precision medicine expert to Clinical Advisory Board, outlining Phase 2 IND plans.

5. Feb 09

   Conference participation

   24h Move

   +4.9%

   Announced virtual fireside chat at Piper Sandler immunology symposium with webcast and meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pde4 inhibitor, prodrugs, terminal ileum

3 terms

pde4 inhibitor medical

"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"

A PDE4 inhibitor is a drug that blocks an enzyme (PDE4) involved in turning off certain cell signals linked to inflammation and brain activity; blocking it lets those signals persist and can reduce inflammation or alter nerve-cell behavior. Investors care because this drug class underlies treatments for conditions like chronic inflammatory and neurological disorders, so clinical trial results, regulatory decisions, or patent news can strongly affect a company’s drug pipeline value and stock outlook.

prodrugs medical

"oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum"

Prodrugs are medicine compounds designed to be inactive or less active when taken and then converted inside the body into the active drug. Like a packaged meal that needs cooking before it can be eaten, they can improve how a medicine is absorbed, reduce side effects, or extend patent and dosing advantages; investors watch prodrugs because these properties affect regulatory approval, market competitiveness, development costs, and potential revenue.

terminal ileum medical

"designed for targeted delivery to the terminal ileum and colon"

The terminal ileum is the final segment of the small intestine that connects to the large intestine; think of it as the doorway between two rooms of the digestive tract where nutrients are absorbed and waste moves on. It matters to investors because many gastrointestinal diseases, targeted drugs, diagnostic tests, and surgical procedures focus on this specific site, so outcomes or regulatory news about treatments affecting the terminal ileum can materially influence clinical trial results, approvals, and a company’s financial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET

Access the webcast here

Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026.

The Company’s virtual presentation is scheduled for Thursday, April 16, 2026, from 2:15 PM to 2:55 PM ET in Track 3. A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered for the conference.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug.

Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. For more information, please go to www.palisadebio.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Palisade Bio (PALI) presenting at the Needham Healthcare Conference?

The Palisade Bio presentation is on April 16, 2026, from 2:15–2:55 PM ET. According to the company, the talk is in Track 3 and will feature CEO JD Finley and Dr. Mitchell Jones, covering corporate and clinical updates.

How can investors watch the Palisade Bio (PALI) Needham presentation live?

Investors can watch the presentation via a live webcast on palisadebio.com. According to the company, the webcast is on the Events page in Investors, and a replay will be archived for a limited time after the live event.

Will a replay of the Palisade Bio (PALI) Needham presentation be available?

Yes, a replay will be available after the live presentation and archived for a limited time. According to the company, the replay will be accessible from the Events page in the Investors section of palisadebio.com.

Who will present for Palisade Bio (PALI) at the Needham conference?

CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones will present for Palisade Bio. According to the company, they will discuss company developments and be available for one-on-one investor meetings.

Can investors schedule one-on-one meetings with Palisade Bio (PALI) management at Needham?

Yes, management will accept one-on-one meetings with qualified, registered investors during the conference. According to the company, meetings require registration for the Needham conference and qualification by the event organizers.

Where will the Palisade Bio (PALI) webcast be hosted online?

The webcast will be hosted on the Events page of the Investors section at palisadebio.com. According to the company, that page will provide the live stream during the presentation and access to the archived replay afterward.